Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.

摘要: OBJECTIVE: Patients using acetylsalicylic acid (aspirin) have an increased risk of upper gastrointestinal discomfort. The aim this study was to assess whether gastric suppression improves symptoms in patients low-dose aspirin for cardiovascular disease. METHODS: In a double-blind, placebo-controlled randomised trial, 150 (80 mg) with who had been admitted at the Coronary Care Unit University Medical Center Nijmegen were assigned treatment rabeprazole (20 mg once daily) or placebo 4 weeks. Treatment success, defined as complete symptom relief, could be evaluated 143 patients. RESULTS: At weeks after randomization, 34 73 therapy (47%) compared 30 70 given (43%) reported relief (P = 0.54). Rabeprazole did lead 52% improvement heartburn [25% vs. 16%; odds ratio (OR) 0.48, 95% confidence interval (CI): 0.24-0.97]. Epigastric pain, regurgitation, bloating and nausea not statistically change treatment. history dyspepsia more often success comparison those without (75% 40%; OR 0.25, CI: 0.09-0.70). CONCLUSIONS: Proton-pump inhibitor significantly reduced heartburn, but other associated symptoms.